Compile Data Set for Download or QSAR
Report error Found 1037 Enz. Inhib. hit(s) with all data for entry = 11849
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652462(US20240059691, Example 1042 | 5-N-[(2-{5H,6H,7H,8H...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652548(US20240059691, Example 1282 | N5-((4-methyl-6-(3-(...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652564(US20240059691, Example 1303 | N5-((4-methyl-6-(8-m...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652566(US20240059691, Example 1305 | (S*)-N5-((4-methyl-6...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652569(US20240059691, Example 1309 | N5-((4-ethyl-6-(3-(t...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652573(US20240059691, Example 1313 | 2-chloro-N-((4-methy...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652680(US20240059691, Example 4297 | N5-((2-((3-isopropyl...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652682(US20240059691, Example 4299 | 5-N-({2-[(1-isopropy...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652684(US20240059691, Example 4301 | 4-{[(4-{[(1-aminoiso...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652688(US20240059691, Example 4307 | 4-fluoro-6-N-[(2-{5H...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652690(US20240059691, Example 4309 | 4-chloro-6-N-{[2-({2...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652713(US20240059691, Example 4428 | 3-[(4-{[(1-amino-4-c...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652715(US20240059691, Example 4430 | (S*)-N5-((2-((5,6,7,...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652716(US20240059691, Example 4431 | (R*)-N5-((2-((5,6,7,...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652744(US20240059691, Example 4464 | 8-methyl-N-((2-((1-m...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652764(US20240059691, Example 9005 | N5-((3-methyl-5-(3-(...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652428(US20240059691, Example 1008 | N-({6-[(1-methylpipe...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652428(US20240059691, Example 1008 | N-({6-[(1-methylpipe...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652428(US20240059691, Example 1008 | N-({6-[(1-methylpipe...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652432(US20240059691, Example 1012 | 6-N-({6-[(1-isopropy...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652433(US20240059691, Example 1013 | 6-N-({2-[(1-methylpi...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652520(US20240059691, Example 1248 | methyl 4-(((6-(((1-m...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652613(US20240059691, Example 2193 | N-[(4-{[(1-methylpip...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652613(US20240059691, Example 2193 | N-[(4-{[(1-methylpip...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652613(US20240059691, Example 2193 | N-[(4-{[(1-methylpip...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652613(US20240059691, Example 2193 | N-[(4-{[(1-methylpip...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652617(US20240059691, Example 2197 | 5-N-[(2-fluoro-4-{[(...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652617(US20240059691, Example 2197 | 5-N-[(2-fluoro-4-{[(...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652617(US20240059691, Example 2197 | 5-N-[(2-fluoro-4-{[(...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652617(US20240059691, Example 2197 | 5-N-[(2-fluoro-4-{[(...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652618(US20240059691, Example 2198 | N6-(2-fluoro-4-((((4...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652619(US20240059691, Example 2199 | N6-(2-fluoro-4-((((4...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652621(US20240059691, Example 2201 | 5-N-[(4-{[(1-ethylpi...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652621(US20240059691, Example 2201 | 5-N-[(4-{[(1-ethylpi...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652621(US20240059691, Example 2201 | 5-N-[(4-{[(1-ethylpi...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652622(US20240059691, Example 2202 | 6-N-[(4-{[(1-ethylpi...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652643(US20240059691, Example 3254 | 6-N-({1-[2-(1-methyl...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652646(US20240059691, Example 4260 | 5-N-[[2-[(1-methyl-4...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652646(US20240059691, Example 4260 | 5-N-[[2-[(1-methyl-4...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652646(US20240059691, Example 4260 | 5-N-[[2-[(1-methyl-4...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652646(US20240059691, Example 4260 | 5-N-[[2-[(1-methyl-4...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652647(US20240059691, Example 4261 | 6-N-({2-[(1-methylpi...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652744(US20240059691, Example 4464 | 8-methyl-N-((2-((1-m...)
Affinity DataIC50: 2nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasminogen(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652421(US20240059691, Example 1001 | 6-N-({6-[(1-methylpi...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652422(US20240059691, Example 1002 | 5-N-({4-[(1-methylpi...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasminogen(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652422(US20240059691, Example 1002 | 5-N-({4-[(1-methylpi...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetSerine protease 1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652422(US20240059691, Example 1002 | 5-N-({4-[(1-methylpi...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652424(US20240059691, Example 1004 | 3-chloro-N-(4-((1-me...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652425(US20240059691, Example 1005 | 6-N-({6-[(1-methylpi...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652426(6-N-[(6-{5H,6H,7H,8H-imidazo[1,2-a]pyridin-7-ylmet...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1037 total ) | Next | Last >>
Jump to: